コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 current radiotherapy in patients with muscle-invasive bladder cancer.
2 ion of severe dysplasia/carcinoma in situ to invasive bladder cancer.
3 upport the aggressive surgical management of invasive bladder cancer.
4 five cystectomy specimens from patients with invasive bladder cancer.
5 f life of patients undergoing cystectomy for invasive bladder cancer.
6 apy over radical cystectomy alone for muscle-invasive bladder cancer.
7 and BM staining as prognostic indicators in invasive bladder cancer.
8 servation in the management of patients with invasive bladder cancer.
9 change management of patients with nonmuscle invasive bladder cancer.
10 NAs to help evaluate patients with nonmuscle invasive bladder cancer.
11 ladder preservation for patients with muscle invasive bladder cancer.
12 urrent use with radiotherapy to treat muscle-invasive bladder cancer.
13 ve the cure rates of patients diagnosed with invasive bladder cancer.
14 podia of angiogenic endothelial tip cells in invasive bladder cancer.
15 hemotherapy regimen for patients with muscle invasive bladder cancer.
16 h metastatic disease in patients with muscle-invasive bladder cancer.
17 native to cystectomy in patients with muscle-invasive bladder cancer.
18 verall survival after radical cystectomy for invasive bladder cancer.
19 cystectomy or radiotherapy alone, for deeply invasive bladder cancer.
20 tcome as first-line adjunctive treatment for invasive bladder cancer.
21 from controls and also nonmuscle from muscle-invasive bladder cancer.
22 tcomes and quality of life for patients with invasive bladder cancer.
23 ection (PLND) is the preferred treatment for invasive bladder cancer.
24 on markers and novel therapeutic targets for invasive bladder cancer.
25 gnature to predict progression in non-muscle-invasive bladder cancer.
26 tential prognostic and therapeutic value for invasive bladder cancer.
27 romboxane synthase (TXAS) gene expression in invasive bladder cancer.
28 emains the gold standard for treating muscle-invasive bladder cancer.
29 cal mainstay for the treatment of non-muscle-invasive bladder cancer.
30 ed significant independent associations with invasive bladder cancer.
31 ectomy remains the gold-standard therapy for invasive bladder cancer.
32 cial component of the surgical management of invasive bladder cancer.
33 resented both superficial bladder tumors and invasive bladder cancers.
34 ers, and (3) PGDH is completely lost in most invasive bladder cancers.
35 atment for localized and regionally advanced invasive bladder cancers.
36 Of 432 newly evaluated patients with muscle-invasive bladder cancer, 151 were treated by standard ra
38 its applicability in case studies of muscle-invasive bladder cancer and essential thrombocythemia.
40 receptor I (IGF-IR) is up-regulated in human invasive bladder cancer and promotes migration and invas
41 nts completing combined-modality therapy for invasive bladder cancer and retaining their native bladd
42 ant role in non-invasive than that in muscle-invasive bladder cancer and suggest that cohesin complex
43 ing intermediate, were present in high-grade invasive bladder cancers and associated with more freque
44 el to help predict progression of non-muscle-invasive bladder cancers and delineate a systematic, gen
45 mainstay definitions of high-risk nonmuscle invasive bladder cancer are based on grade and stage.
47 oma of the urinary bladder (a model of human invasive bladder cancer) as well as adjacent normal tiss
48 ell, and squamous cell carcinoma subtypes of invasive bladder cancer, as well as in T24, J82, and UM-
49 for muscle-invasive and high-risk nonmuscle-invasive bladder cancer (BCa), but is associated with si
50 ign and interpretation of clinical trials in invasive bladder cancer but also help to identify and op
51 surgery achieve similar cure rates in muscle-invasive bladder cancer, but the choice of which treatme
52 we created a novel transgenic mouse model of invasive bladder cancer by targeting an active dimerized
54 ubstrate (HA)-gel technique, showed that the invasive bladder cancer cell lines secrete elevated leve
55 eport a comprehensive analysis of 412 muscle-invasive bladder cancers characterized by multiple TCGA
60 kers may have prognostic value in non-muscle invasive bladder cancer for guiding optimal treatment of
63 umors, several histopathological subtypes of invasive bladder cancer have been identified as being mo
64 Patients with locally 'advanced' or muscle invasive bladder cancer have higher mortality rates than
69 cystectomy and urinary diversion for muscle invasive bladder cancer), kidney surgery (nephrectomy, d
70 cantly associated with progression to muscle-invasive bladder cancer (log-rank test; P < 0.001) in th
75 the immune microenvironment of cancer.Muscle-invasive bladder cancer (MIBC) is a potentially lethal d
77 is viewed as the standard of care for muscle-invasive bladder cancer (MIBC), radiotherapy-based, blad
78 g combined-modality therapy (CMT) for muscle-invasive bladder cancer (MIBC), reserving cystectomy for
80 chemotherapy is standard of care for muscle-invasive bladder cancer (MIBC); however, it is infrequen
86 pose Many patients with high-risk non-muscle-invasive bladder cancer (NMIBC) are either refractory to
87 rexpression of fibulin-3 in T2 vs non-muscle-invasive bladder cancer (NMIBC) by quantitative reverse
88 PURPOSE OF REVIEW: As high-risk nonmuscle invasive bladder cancer (NMIBC) has a high propensity to
91 with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) without carcinoma in sit
95 In summary, these data support a model of invasive bladder cancer pathogenesis in which both the p
99 -12-82 GG polymorphisms were associated with invasive bladder cancer risk [odds ratio (OR), 2.60; 95%
102 Patients were enrolled if they had muscle-invasive bladder cancer (stage T2 to T4a) and were to be
105 so shown to localize to the nucleus of human invasive bladder cancers that were primarily composed of
108 nstrated that the IGF-IR is overexpressed in invasive bladder cancer tissues and promotes motility an
109 nstrated that the IGF-IR is overexpressed in invasive bladder cancer tissues compared with nonmaligna
110 e randomly assigned 360 patients with muscle-invasive bladder cancer to undergo radiotherapy with or
111 n frozen tumor samples from 42 patients with invasive bladder cancer treated by cystectomy with monoc
112 emotherapy does benefit patients with muscle-invasive bladder cancer, we reviewed all phase II and II
113 s of ET-1 are higher in patients with muscle-invasive bladder cancers, which are associated with high
114 ologic reports from 268 patients with muscle-invasive bladder cancer who received radical cystectomy.
115 les of blood vascular endothelium from human invasive bladder cancer with normal bladder tissue, we f
117 ture, which effectively distinguishes muscle-invasive bladder cancer with worse clinical prognosis fr
118 lysed p73 mutations in 23 unselected primary invasive bladder cancers with matched normal tissues and
119 er is the highest risk subtype of non-muscle-invasive bladder cancer, with highly variable prognosis,
120 ajor treatment modality used to treat muscle-invasive bladder cancer, with patient outcomes similar t
121 bladder epithelial HCV29 cells versus highly invasive bladder cancer YTS1 cells, both derived from tr
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。